Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
m (Text replacement - "[[File:" to "[[:File:") |
||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. <ref name="insert">[https://www.poteligeohcp.com/Content/files/prescribing-information.pdf Mogamulizumab (Poteligeo) package insert]</ref><ref>[[File:Mogamulizumab.pdf | Mogamulizumab (Poteligeo) package insert (locally hosted backup)]]</ref><ref>[https://www.poteligeohcp.com Poteligeo manufacturer's website]</ref> | + | From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. <ref name="insert">[https://www.poteligeohcp.com/Content/files/prescribing-information.pdf Mogamulizumab (Poteligeo) package insert]</ref><ref>[[:File:Mogamulizumab.pdf | Mogamulizumab (Poteligeo) package insert (locally hosted backup)]]</ref><ref>[https://www.poteligeohcp.com Poteligeo manufacturer's website]</ref> |
==Diseases for which it is used== | ==Diseases for which it is used== |
Revision as of 03:59, 20 September 2021
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. [1][2][3]
Diseases for which it is used
History of changes in FDA indication
- 8/8/2018: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (Based on MAVORIC)
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo